Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of SGB-9768 in primary IgA nephropathy, C3 glomerulopathy, and IC-MPGN
ChiCTR2500098240Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Mar 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SGB-9768 in IgA nephropathy (IgAN), Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) (3 cohorts), sponsored by Peking University First Hospital. Primary endpoint: Change from baseline in 24-hour urine protein-to-creatinine ratio. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
SGB-9768
03
Conditions
IgA nephropathy (IgAN)Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on ChiCTR2500098240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098240.